Subscribe to RSS
DOI: 10.1055/s-0030-1267915
© Georg Thieme Verlag KG Stuttgart · New York
Somatostatin Analogues do not Affect Calcium Metabolism in Patients with Acromegaly and Primary Hyperparathyroidism due to MEN 1-Like Syndrome
Publication History
received 26.06.2010
accepted 29.09.2010
Publication Date:
22 October 2010 (online)

Abstract
Patients with clinical features of MEN 1 without mutations in the menin gene fulfill the criteria of MEN1-like syndrome. Primary hyperparathyroidism (PHP) is the most frequent clinical finding in both syndromes and is usually treated by surgery. However, PHP has been reported to respond to somatostatin analogues (SSA) in MEN 1 patients. 7 patients with PHP in the context of MEN 1-like syndrome (and absence of mutations in the menin gene) were enrolled in the study and treated with SSA for 6 months for the non-PHP disease before parathyroidectomy. Serum ionized calcium, phosphorus, and PTH concentrations, and 24-h urinary calcium and phosphorus excretion were measured before and after SSA therapy. Mean serum ionized calcium, phosphorus, and PTH concentrations did not significantly change after a 6-month course with SSA. SSA scintigraphy did not reveal uptake in the neck region corresponding to the parathyroid adenoma identified at surgery and confirmed at histology. However, immunohistochemistry revealed SS-type 2A receptor in parathyroid tissue samples of 6 out of 7 patients. SSA therapy does not affect calcium-phosphorus metabolism in patients with MEN 1-like syndrome, suggesting that the drug has no role in controlling PHP in these subset of patients.
Key words
acromegaly - somatostatin analogues - hyperparathyroidism - MEN 1-like
References
- 1
Brandi ML, Gagel RF, Angeli A, John P, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips JMP, Lombardi G, Mannelli M, Pacini F, Ponder BAJ, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells SA, Marx SJ.
Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2.
J Clin Endocrinol Metab.
2001;
86
5658-5671
MissingFormLabel
- 2
Marini F, Carbonell Sala S, Falchetti A, Caramelli D, Brandi ML.
The genetic ascertainment of multiple endocrine neoplasia type 1 syndrome by ancient
DNA analysis.
J Endocrinol Invest.
2008;
31
905-909
MissingFormLabel
- 3
Georgitsi M, Raitila A, Karhu A, van der Luijt RB, Aalfs CM, Sane T, Vierimaa O, Mäkinen MJ, Tuppurainen K, Paschke R, Gimm O, Koch CA, Gündogdu S, Lucassen A, Tischkowitz M, Izatt L, Aylwin S, Bano G, Hodgson S, De Menis E, Launonen V, Vahteristo P, Aaltonen LA.
Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia.
J Clin Endocrinol Metab.
2007;
92
3321-3325
MissingFormLabel
- 4
Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Höfler H, Fend F, Graw J, Atkinson MJ.
Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats
and humans.
Proc Natl Acad Sci (USA).
2006;
103
15558-15563
MissingFormLabel
- 5
Agarwal SK, Mateo CM, Marx SJ.
Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine
neoplasia type 1 and related states.
J Clin Endocrinol Metab.
2009;
94
1826-1834
MissingFormLabel
- 6
Corleto VD, Nasoni S, Panzuto F, Cassetta S, Delle Fave G.
Somatostatin receptor subtypes: basic pharmacology and tissue distribution.
Dig Liver Dis.
2004;
36
8-16
MissingFormLabel
- 7
Faggiano A, Tavares LB, Tauchmanova L, Milone F, Mansueto G, Ramundo V, De Caro ML, Lombardi G, De Rosa G, Colao A.
Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism
(PHP) in multiple endocrine neoplasia type 1 (MEN1) patients.
Clin Endocrinol.
2008;
69
756-762
MissingFormLabel
- 8
Akerström G, Stålberg P.
Surgical management of MEN-1 and -2: state of the art.
Surg Clin North Am.
2009;
89
1047-1068
MissingFormLabel
- 9
Tonelli F, Marcucci T, Giudici F, Falchetti A, Brandi ML.
Surgical approach in hereditary hyperparathyroidism.
Endocr J.
2009;
56
827-841
MissingFormLabel
- 10
Giustina A, Barkan A, Chanson P, Grossman A, Hoffman A, Ghigo E, Casanueva F, Colao A, Lamberts S, Sheppard M, Melmed S.
Guidelines for the treatment of growth hormone excess and growth hormone deficiency
in adults.
J Endocrinol Invest.
2008;
31
820-838
MissingFormLabel
- 11
Krennings EP, Kwekkeboom DJ, Oei HY, de Jong RJ, Dop FJ, de Herder WW, Reubi JC, Lamberts SW.
Somatostatin receptor scintigraphy in carcinoids, gastrinomas and Cushing's syndrome.
Digestion.
1994;
55
(S 39)
54-59
MissingFormLabel
- 12
Takei M, Suzuki M, Kajiya H, Ishii Y, Tahara S, Miyakoshi T, Egashira N, Takekoshi S, Sanno N, Teramoto A, Osamura RY.
Immunohistochemical detection of somatostatin receptor (SSTR) subtypes 2A and 5 in
pituitary adenoma from acromegalic patients: good correlation with preoperative response
to octreotide.
Endocr Pathol.
2007;
18
208-216
MissingFormLabel
- 13
Volante M, Brizzi MP, Faggiano A, La Rosa S, Rapa I, Ferrero A, Mansueto G, Righi L, Garancini S, Capella C, De Rosa G, Dogliotti L, Colao A, Papotti M.
Somatostatin receptor type 2° immunohistochemistry in neuroendocrine tumors: a proposal
of scoring system correlated with somatostatin receptor scintigraphy.
Mod Pathol.
2007;
20
1172-1182
MissingFormLabel
- 14
Hofland LJ, Lamberts SW.
Somatostatin receptors in pituitary function, diagnosis and therapy.
Front Horm Res.
2004;
32
235-252
MissingFormLabel
- 15
Vezzosi D, Bennet A, Rochaix P, Courbon F, Selves J, Pradere B, Buscail L, Susini C, Caron P.
Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan
scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies.
Eur J Endocrinol.
2005;
152
757-767
MissingFormLabel
- 16
Boulahdour H, Bertrand A, Klingelschmitt S, Rudenko B, Loboguerrero A, Bidet A, Mation G, Cardot J.
Parathyroid adenoma visualization on Octreotide Scintigraphy.
Clin Nucl Med.
2002;
27
304-305
MissingFormLabel
- 17
Broson-Chazot F, Houzard C, Ajzenberg C, Nocaudie M, Duet M, Mundler O, Marchandise X, Epelbaum J, Gomez De Alzaga M, Schäfer J, Meyerhof W, Sassolas G, Warnet A.
Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas:
correlation with hormonal and visual responses to octreotide.
Clin Endocrinol.
1997;
47
589-598
MissingFormLabel
- 18
Dreijerink KM, Lips CJ, Timmers HT.
Multiple endocrine neoplasia type 1: a chromatin writer's block.
J Intern Med.
2009;
266
53-59
MissingFormLabel
- 19
Hublitz P, Albert M, Peters AHFM.
Mechanisms of transcriptional repression by histone lysine methylation.
Int J Dev Biol.
2009;
53
335-354
MissingFormLabel
- 20
Ybarra J, Moisès J, Torregrosa JV, Madhun ZT, Schumacher OP.
Effects of octreotide on serum and urine electrolytes in a patient with a parathyroid
carcinoma: clinical case.
Nefrologia.
2001;
21
406-410
MissingFormLabel
Notice:
The title was changed after e-first publication to “Somatostatin Analogues do not Affect Calcium Metabolism in Patients with Acromegaly and Primary Hyperparathyroidism due to MEN 1-Like Syndrome”.
Correspondence
F. BogazziMD
Department of Endocrinology
University of Pisa
Ospedale Cisanello
Via Paradisa 2
56124 Pisa
Italy
Phone: +39/050/997348
Fax: +39/050/578772
Email: fbogazzi@hotmail.com